Sartorius Stedim Biotech (56S1) Income Statement
Sartorius Stedim Biotech Income Statement
Last quarter (Q3 2026), Sartorius Stedim Biotech's total revenue was $762.10M, an increase of 7.99% from the same quarter last year. In Q3, Sartorius Stedim Biotech's net income was $95.50M. See Sartorius Stedim Biotech’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 2.97B | $ 2.78B | $ 2.78B | $ 3.49B | $ 2.89B | |
| $ 1.35B | $ 1.21B | $ 1.23B | $ 1.82B | $ 1.55B | |
| $ 796.30M | $ 836.10M | $ 749.00M | $ 764.10M | $ 640.34M | |
| Depreciation and Amortization | $ 318.10M | $ 301.70M | $ 237.60M | $ 181.70M | $ 141.56M |
| $ 867.10M | $ 670.50M | $ 755.70M | $ 1.33B | $ 811.96M | |
| $ 549.00M | $ 370.60M | $ 484.50M | $ 1.10B | $ 912.67M | |
| $ -175.80M | $ -151.40M | $ -83.40M | $ 29.20M | $ -265.95M | |
| $ 373.20M | $ 219.20M | $ 401.10M | $ 1.13B | $ 646.72M | |
| $ 265.60M | $ 175.10M | $ 309.70M | $ 876.10M | $ 414.40M | |
| Per Share Metrics | |||||
| Basic EPS | $ 2.73 | $ 1.81 | $ 3.36 | $ 9.51 | $ 4.50 |
| Diluted EPS | $ 2.73 | $ 1.81 | $ 3.36 | $ 9.51 | $ 4.50 |
| Weighted Average Shares Outstanding | 97.30M | 96.78M | 92.16M | 92.16M | 92.18M |
| Weighted Average Shares Outstanding (Diluted) | 97.30M | 96.78M | 92.16M | 92.16M | 92.18M |
Currency in EUR